GHK-Cu peptide rescues behavior in middle-aged mice via distinct hippocampal aging programs depending on administration route

Brain aging and cognitive decline are widespread challenges, with age-related cognitive impairment affecting millions. Current treatments for neurodegenerative conditions like Alzheimer's disease (AD) often target single pathogenic mechanisms, leading to limited success. The complexity of AD pathogenesis, involving multiple pathways, suggests that broader-acting agents or combination therapies might be more effective. GHK-Cu, a naturally occurring copper-binding peptide, has shown neuroprotective properties and the ability to modulate multiple pathways, making it a candidate for addressing the multifaceted nature of brain aging and cognitive impairment.

This preclinical study investigated the effects of GHK-Cu in middle-aged mice. The peptide was administered via two distinct routes: intraperitoneal (IP) injection and intranasal (IN) delivery. The primary objective was to assess whether GHK-Cu could induce behavioral rescue in these aging animals. Additionally, the researchers aimed to characterize the impact of each administration route on the hippocampal aging programs, suggesting an analysis of gene expression or proteomic changes within the hippocampus to understand the underlying molecular mechanisms of the observed behavioral improvements.

GHK-Cu treatment successfully induced a significant behavioral rescue in middle-aged mice, irrespective of the administration route. This suggests that the peptide can effectively cross the blood-brain barrier or exert systemic effects that translate to cognitive and behavioral improvements. However, a key finding was the observation of divergent hippocampal aging programs depending on whether GHK-Cu was delivered intraperitoneally or intranasally. This indicates that while both routes achieve a beneficial outcome, the specific molecular pathways and cellular responses within the hippocampus differ significantly. For instance, intranasal delivery, which can bypass the systemic circulation and directly target the brain, might engage distinct sets of genes or signaling cascades compared to systemic intraperitoneal administration. This divergence implies that the route of administration may fine-tune the therapeutic effects and underlying biological adaptations, potentially offering a way to optimize GHK-Cu's impact on specific aspects of brain aging. The study highlights that the 'how' of delivery is as crucial as the 'what' in modulating complex biological processes like aging.